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At a glance commentary:  
Scientific Knowledge on the Subject 
Gene transfer to the airway epithelium is more difficult than originally anticipated. Until now 
viral gene transfer agents have not been useful for the treatment of chronic lung disease such 
cystic fibrosis (CF), due to immunogenicity which prevent successful repeat administration.  
Lentivirus-based vectors are a notable exception.  
 
What This Study Adds to the Field 
Moving novel therapies to the clinic requires that relevant evidence for both safety and 
efficacy is gathered in appropriate models. Here, we begin to place this vector onto a 
translational pathway to the clinic and provide a body of supportive evidence for F/HN-
pseudotyped SIV as a potential gene transfer agent for CF including a) life-time gene 
expression and efficient repeat administration in mouse lung, b) lack of chronic toxicity, c) 
persistent gene expression in human ex vivo models. 
 
 
 
Running Title: F/HN pseudotyped lentivirus for airway gene transfer 
Subject category: 9.17 Cystic fibrosis – Translational & Clinical Studies 
Word count: 4707 
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Abstract  
Rational: Our ongoing efforts to improve pulmonary gene transfer thereby enabling gene 
therapy for the treatment of lung diseases such as cystic fibrosis (CF) has led to the 
assessment of a lentiviral vector (SIV) pseudotyped with the Sendai virus envelope proteins F 
and HN. Objectives: Here, we begin to place this vector onto a translational pathway to the 
clinic, by addressing some key milestones that have to be achieved. Main results: These 
include: (1) a single dose produces lung expression for the life-time of the mouse 
(approximately 2 years), (2) only brief contact time is needed to achieve transduction, (3) 
repeated daily administration leads to a dose-related increase in gene expression, (4) repeated 
monthly administration to mouse lower airways is feasible without loss of gene expression, 
(5) there is no evidence of chronic toxicity during a 2 year study period, (6) F/HN-SIV 
transduction generates persistent gene expression in human differentiated airway cultures, 
and human lung slices and transduces freshly obtained primary human airway epithelial cells. 
Conclusions: The data support F/HN-pseudotyped SIV as a promising vector for pulmonary 
gene therapy for a number of diseases including CF and we are now undertaking the 
necessary refinements to progress this vector into clinical trials.  
 
Abstract word count: 201 
Keywords: lentivirus, cystic fibrosis, gene therapy, lung, gene transfer  
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Introduction 
Gene transfer to the airway epithelium has been more difficult than originally anticipated, 
largely because of significant extra- and intracellular barriers in the lung 
1
. In general, viral 
vectors are more adapted to overcoming these barriers than non-viral gene transfer agents. 
Viral vectors that have a natural tropism for the airway epithelium such as those derived from 
adenovirus (Ad), adeno-associated virus (AAV) and Sendai virus (SeV), have been evaluated 
for cystic fibrosis (CF) gene therapy. SeV vector, in particular, leads to log orders higher 
gene expression than non-viral formulation when applied to the apical surface of airway 
epithelial cells  
2;3
. However, gene expression is transient and repeated administration is 
inefficient 
4;5
. These vectors are, therefore, unlikely to solve the challenge of life-long gene 
therapy treatment for CF. 
 
Lentiviral vectors are commonly pseudotyped with the G-glycoprotein from the vesicular 
stomatitis virus (VSV-G) allowing for a broad tissue tropism. However, VSV-G-pseudotyped 
vectors are comparatively inefficient at transducing airway epithelial cells and require the 
addition of tight junction openers such as lyso-phosphatidylcholine (LPC) to allow virus 
entry into airway cells.
6;7
 Several groups have attempted to further improve lentiviral vector 
uptake into airway epithelium by changing the viral envelope proteins. Glycoproteins from 
Ebola or Marburg virus that naturally transfect airway epithelial cells via the apical 
membrane showed early promise, 
8
 but have more recently been superseded by viral vectors 
pseudotyped with the influenza M2 envelope glycoprotein, 
9
 baculovirus protein GP64 
10
 or 
the Sendai virus-derived F and HN envelope proteins. 
11;12
  
 
The F/HN-pseudotyped simian immunodeficiency viral vector (F/HN-SIV) transduces rodent 
airway epithelial cells  in vitro.
 12
 Recently, we have shown  that F/HN-SIV leads to 
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persistent expression in the mouse nose (more than 1 year) importantly allowing for monthly 
repeat administration without significant loss of efficacy 
11
.  It is currently unclear, whether 
the prolonged expression is due to vector integration into pulmonary stem or progenitor cells, 
or due to the long life-span of airway epithelial cells, which as recently reported, may have a 
half-life of up to 17 months 
13
. It is also unclear how upon repeated administration the viral 
vector evades the immune system, although interestingly liposome which contain Sendai 
virus proteins (HVJ-liposome) can also be repeatedly administered 
14
.  This feature, as well as 
the efficient and prolonged expression profile and the ability to administer through the apical 
surface of the respiratory epithelium without pre-conditioning, makes the vector an attractive 
candidate for treating CF which is a chronic disease and will require life-long correction of 
the genetic defect in airway epithelial cells.  
 
Here, we have further developed the F and HN pseudotyped SIV towards clinical evaluation. 
We show that repeated administration to the mouse lower airways is feasible. We also 
confirm the long-term safety profile of this viral vector and show that it transduces the 
relevant human airway epithelial cells required for CF gene therapy.  
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Material and Methods 
Viral vector production 
Purified and concentrated F/HN-SIV expressing firefly luciferase (F/HN-SIV-Lux) or 
enhanced green fluorescent protein (F/HN-SIV-GFP) under the transcriptional control of the 
CMV enhancer/promoter, were prepared and titrated as previously described 
11
 (see online 
supplement for further details). 
 
Mouse lung transfection 
Female C57BL/6N mice (6–8 weeks old) were used (see online supplements for additional 
details). 100 l viral vector in D-PBS was administered to the mouse nose and “sniffed” into 
the lung as previously described 
15
 (see Results and Figures for details about vector titers 
used) and gene expression quantified (see online supplement for further details). 
 
For the daily repeat administration experiments, groups of mice were treated over 10 days 
with either nine daily doses of D-PBS followed by a single dose of F/HN-SIV-Lux, five daily 
doses of D-PBS followed by five daily doses of F/HN-SIV-Lux or ten daily doses of F/HN-
SIV-Lux. Gene expression was analyzed 28 days after the final F/HN-SIV-Lux 
administration.  
 
For the monthly repeat administration experiments groups of mice were transduced with 
either one dose of F/HN-SIV-Lux (single dose group), or two doses of F/HN-SIV-GFP (day 
0, day 28), followed by F/HN-SIV-Lux on day 56 (repeat dose group). Importantly, mice 
receiving F/HN-SIV-Lux (single dose group) and F/HN-SIV-Lux on day 56 (repeat dose 
group) were of similar age and were transduced at the same time. Gene expression was 
analyzed 28 days after F/HN-SIV-Lux administration.  
7 | P a g e  
 
 
Toxicology 
Over the 24 months study period mice were carefully observed daily and were given a full 
clinical examination every 2 weeks (including palpation of the abdomen for tumors) by an 
experienced animal technician, and bodyweight was recorded. Histological assessment was 
performed in mice that showed signs of illness throughout the study period. In addition lungs 
from asymptomatic mice culled at the end of the 24 month study period were also analysed 
(see online supplement for more details). 
 
Histological assessment of GFP expression 
Mouse lungs were transduced with F/HN-SIV-GFP (10
8
 TU/mouse in 100 l) by nasal 
sniffing. Animals receiving D-PBS only were used as negative controls (n=4/group). One 
month after transduction animals were culled and GFP expression was assessed in lung tissue 
(see online supplement for more details).  
 
Gene transfer into relevant pre-clinical model 
Gene transfer into human ALI cultures, human nasal brushings and lung slices was performed 
as described in the online supplements.  
 
Statistical analysis 
ANOVA followed by a Bonferroni post-hoc test or Kruskal-Wallis test followed by Dunns-
multiple comparison post-hoc test was performed for multiple group comparison after 
assessing parametric and non-parametric data distribution with the Kolmogorov-Smirnov 
normality test, respectively. An independent student t-test or a Mann-Whitney test was 
performed for two group parametric and non-parametric data as appropriate. Pearsons 
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correlation was performed for parametric data. All analyses were performed using GraphPad 
Prism4 and the null hypothesis was rejected at p<0.05. 
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Results 
Gene Expression in mouse lung persists and is stable  
We first assessed if F/HN-SIV produced measurable levels of luciferase in murine lower 
airways (lungs), and if this expression was dose-related. Mice were transduced with F/HN-
SIV-Lux (10
7
 or 10
8 
TU/mouse in 100 l total volume) by nasal sniffing (n=8/group) or 
received D-PBS (n=8). Two days after transduction mice, were culled and luciferase 
expression quantified in lung homogenates. Luciferase expression was detectable and dose-
related (10
7
 TU/mouse: 2.0±0.3 relative light units (RLU)/mg protein, 10
8
 TU/mouse: 
27.0±6.4 RLU/mg protein, p<0.01, D-PBS: 0.01±0.03 RLU/mg). However, gene expression 
was also production batch-related (see online supplement).     
 
We next assessed if expression in mouse lungs persisted. Mice were transduced with F/HN-
SIV-Lux (5x10
8
 TU/mouse in 100 l total volume) by nasal sniffing (n=8 in two independent 
experiments) or received D-PBS (negative controls, n=6) and luciferase expression was 
quantified using in vivo bioluminescence imaging at regular intervals for up to 22 months. 
Luciferase-mediated photon emission was detectable in all treated mice 2 months after 
transduction (SIV: 362,660±63,922 photons/sec/cm
2
, n=8, D-PBS: 66,535±4868 
photons/sec/cm
2
, n=6, p<0.005). Seven out of eight mice survived for 16 months and four out 
of the eight mice survived until termination of the experiment at 22 months. All of the SIV 
transduced mice had detectable luciferase expression at all time points. Photon emission 
increased modestly, but significantly (p<0.005), over time (SIV at 2 months: 381,123 ±70665 
photons/sec/cm
2
, at 16 months: 543,156 ±65234 photons/sec/cm
2
, n=7 mice with data for 
both time-points). This was maintained at 22 months (2 months: 367,485±115923 
photons/sec/cm
2
, 22 months: 1,407.000±435,790 photons/sec/cm
2
, n=4 mice with data for 
10 | P a g e  
 
both time-points). In contrast, photon emission in D-PBS-treated mice remained stable over 
the same time period (Figure 1 A+B).  
 
An increase in photon emission may indicate an increase in luciferase expression potentially 
caused by an increase in the number of luciferase expressing cells over time or may be a 
peculiarity of BLI.  We, therefore, repeated the experiment comparing BLI and post-mortem 
quantification of luciferase expression in lung tissue homogenates in the same animals. Mice 
were transduced with F/HN-SIV (10
7
 TU/mouse, n=8-12/time-point) and at regular intervals 
over a 24 months period (for technical reasons BLI could only be performed between 6 and 
24 months after gene transfer) and post-mortem quantification of luciferase expression in 
lung tissue homogenate was performed in cohorts of mice. Similar to results described above 
photon emission significantly (p<0.001) increased over the study period (BLI 6 months: 
87,915±8871 photons/sec/cm
2
, BLI at 24 months: 310,334±36274 photons/sec/cm
2
) (Figure 
1C), whereas detectable levels of luciferase in tissue homogenate remained stable (Figure 
1D). There was no correlation between in vivo photon emission and luciferase expression 
quantified in tissue homogenates (Spearman r=0.205, p=0.11, n=63 paired data points from 6 
to 24 months). However, luciferase expression quantified in tissue homogenates correlated 
well with photon emission from the same animal when lungs were extracted before BLI 
(Figure 1E) (Spearman r=0.75, p=0.01, n=11 paired data points at 24 months), which implies 
that photon quenching may occur in vivo. Additional technical considerations relating to 
limitations of BLI and virus batch-to-batch variability became apparent in this study (see 
online supplement).  
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To determine what cell types were transduced in the lung we transfected mice with F/HN-
SIV-GFP (10
8
 TU/mouse) or D-PBS (n=4/group) by nasal sniffing and assessed GFP 
expression one months after transduction. GFP expression was detectable in airway epithelial 
cells, and also in the alveolar region (Figure 1F). 
 
F/HN-SIV requires only short contact time to achieve efficient transduction 
We compared prolonged contact time of the vector with the nasal epithelium (via perfusion) 
with very brief contact time (sniffing). The latter led to equally efficient transduction of the 
nasal epithelium as the former (Figs 2A+B). This suggests that a short contact time between 
the viral vector and the target cell may be sufficient for efficient vector uptake into the cells, 
of potential importance in future clinical trials.  
 
Gene expression in the nose also persisted for 15-22 months in seven out of eight mice, but, 
in contrast, to the lung gradually declined by approximately 60% over this period (SIV month 
2: 1,309,000±316,612 photons/sec/cm
2
, month 15: 583,951±228,804 photons/sec/cm
2
, 
p<0.05, n=7/group, D-PBS month 15: 53,021±2325 photons/sec/cm
2
, p<0.005) which may be 
due to different cell types being transduced in nose and lung or different turn-over rates of the 
cells at these two sites. Consistent with our previous data using non-viral gene transfer agents 
16
, intranasal (IN) administration of luciferin (the substrate for luciferase) boosted F/HN-SIV-
Lux derived photon emission in mice that were negative after intraperitoneal (IP) 
administration of luciferin (Figure 2C).  
 
Daily repeat administration to the lung is feasible 
Although gene expression after a single dose of F/HN-SIV persists for the life-time of the 
animal, a single dose may not be sufficient to achieve therapeutic benefit in man. It is, for 
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example, conceivable that the total volume required for delivery the optimal vector titre to the 
human lung may be too large for a single dose and administration may have to be split into 
several doses to accommodate the volume. We, therefore, assessed if repeated daily 
administration of the viral vector is feasible and if this leads to incrementally increased gene 
expression compared to a single dose. Mice (n=8/group) were treated with either F/HN-SIV-
Lux daily for 10 days (10
6
 TU/day in 100 l) or with PBS (100 l) for 5 days followed by 5 
days of F/HN-SIV-Lux (10
6
 TU/day) or with D-PBS for 9 days followed by one day of 
F/HN-SIV-Lux (10
6
 TU/day); Lux expression was quantified 28 days after the last dose. 
Gene expression was significantly correlated (Pearsons r
2
=0.61, p>0.0001) with the number 
of F/HN-SIV-Lux doses given (Figure 3A) and indicated that daily repeat administration is 
feasible and significantly increases transduction efficiency. 
 
Monthly repeat administration to the lung is feasible 
Although a single dose of F/HN-SIV generates persistent gene expression for approximately 
2 years in mice (life-time of the animal) a single dose will unlikely be sufficient to achieve 
clinical benefit for the life-time of a CF patient. Therefore, a crucial question is whether the 
vector can produce gene expression upon repeated administration to the lung. As shown 
above daily administration was feasible, but this timeframe is unlikely to be sufficient for the 
development of effective immune responses to the viral vector. We, therefore, conducted 
repeat administration experiments at monthly dosing intervals, a period we have shown to be 
sufficient for the development of an immune response to other viral vectors 
5;17
. Mice were 
either treated with one dose of F/HN-SIV-Lux (single dose group) or two doses of F/HN-
SIV-GFP (day 0, day 28), followed by F/HN-SIV-Lux on day 56 (repeat dose group). All 
mice received 10
7
 TU in 100 l per dose (n=20/group) and gene expression was analyzed 28 
days after F/HN-SIV-Lux administration. All mice received only one dose of vector carrying 
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a luciferase reporter gene to avoid interference of anti-luciferase antibodies. As shown in 
Figure 3B luciferase expression levels after one and three doses of the viral vector were 
identical and at this vector titer 4 log orders above background levels (p<0.01).  
 
No evidence of chronic toxicity was seen during a 2 year follow-up period 
Chronic toxicity due to insertional mutagenesis is a potential concern with this vector. Here, 
we compared 24 months survival of mice treated with F/HN-SIV-Lux (10
7 
TU/mouse, n=99 
at start of the experiment) or D-PBS (n=48 at start of the experiment). Mortality (Figure 4A) 
and weight (Table 1) in both groups was similar. We also assessed the lungs of D-PBS or 
F/HN-SIV-Lux (10
7 
TU/mouse, n=12/group) treated mice histologically 24 months after 
nasal sniffing; there were no differences in any of the key histological markers (Figure 4B-
D). Eleven D-PBS and 7 F/HN-SIV treated mice were culled due to showing signs of illness 
or found dead during the study. Histological examination revealed a range of pathology 
commonly found in aging C57BL/6N mice equally distributed between the two groups 
(Table 2). 
 
F/HN-SIV transduction of human ex vivo models is feasible 
A. F/HN-SIV achieves persistent gene expression in differentiated human air liquid 
interface (ALI) cultures  
To assess the efficiency of the viral vector in relevant human tissues we transduced human 
ALIs with F/HN-SIV-Lux at MOI 25 or 250 (n=5/group), with D-PBS control (n=3) or with 
GL67A, the most efficient non-viral gene transfer agent for airway epithelium. The latter was 
complexed with a eukaryotic expression plasmid expressing luciferase (10 g pCIKLux per 
ALI equivalent to 3x10
12
 plasmids and an approximate MOI of 7x10
6
) (n=3) and luciferase 
expression followed using BLI for 3 months (representative images are shown in Figure 5A). 
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F/HN-SIV mediated expression was dose-related and persisted for at least 3 months without 
the loss of activity. In contrast transfection with GL67A/pCIKLux was only barely detectable 
at an early time-point (day 2) after transfection (Figure 5B). Lipid-mediated gene transfer 
was associated with cell damage as indicated by the appearance of small holes in the ALIs; 
this was not seen with exposure of the ALIs to the lentiviral vector (data not shown). 
 
B. F/HN-SIV transduces primary human pulmonary cells  
We assessed if F/HN-SIV transduces primary human airway epithelial cells obtained from 
nasal brushings or human lung slices generated from lung resection tissue (Figure 6A). Nasal 
brushings were transduced with F/HN-SIV-Lux at an MOI of 25 and 250 or treated with D-
PBS (n=6/group) and luciferase expression was quantified 24 hr after transduction (cell 
viability precludes longer time scales). Luciferase expression was significantly (p<0.005) 
increased compared to PBS controls (Figure 6B). These results were confirmed in an 
independent experiment (MOI 25:9.7x10
6
±0.9x10
6
, MOI 250: 1.5x10
7
±1.6x10
6
, Negative 
Control: 2762±241 RLU/mg protein, n=4/group) 
 
C. F/HN-SIV achieves persistent gene expression in human and sheep lung slices 
Precision cut human lung slices were transduced with F/HN-SIV-Lux (2x10
7
 TU/slice), or 
remained untransduced, and luciferase expression quantified for 14 days after transduction. 
Assessment of later time-points is currently not feasible due to limited tissue viability 
(Figure 6C). Two independent experiments were performed (see open and closed symbols in 
figure) but data were pooled to allow for robust statistical analysis. Significant (p<0.001) and 
stable gene expression was detectable for at least 14 days (p<0.05) after gene transfer.   
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We also repeated these experiments in sheep lung slices (two independent experiments), 
which generally survive longer than human lung slices when cultured (unpublished data). 
Significant (p<0.001 to p<0.05) and stable luciferase expression was detectable at all time-
points for at least 26 days after transduction (Figure 6D). These results indicate that F/HN–
SIV is able to transduce primary human and sheep pulmonary cells and provides persistent 
expression.  
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Discussion 
The efforts, of one of our team, to improve pulmonary gene transfer and enable gene therapy 
for the treatment of lung diseases such as CF have led to the development of a lentiviral 
vector pseudotyped with the Sendai virus envelope proteins F and HN 
12
. Moving novel 
therapies to the clinic requires that relevant evidence for both safety and efficacy is gathered 
in appropriate models. Here, we begin to place this vector onto a translational pathway to the 
clinic and  provide a body of supportive evidence for F/HN-pseudotyped SIV as a potential 
gene transfer agent for CF. We show that (1) a single dose produces lung expression for the 
life-time of the mouse (approximately 2 years), (2) only brief contact time (seconds) is 
needed to achieve transduction, (3) repeated daily administration leads to a dose-related 
increase in gene expression, (4) repeated monthly administration to mouse lower airways is 
feasible without loss of gene expression, (5) there is no evidence of chronic toxicity during a 
2 year study period, (6) F/HN-SIV transduction generates persistent gene expression in 
human differentiated airway cultures and freshly obtained human lung slices and transduces 
freshly obtained primary human airway epithelial cells. 
 
 At least two previous studies have shown that lentiviral vector-mediated transduction of 
mouse lung leads to persistent (15 and 24 months) gene expression in the murine lower 
airways 
18;19
. However, both studies used a VSV-G pseudotyped lentiviral vector which 
almost exclusively transduces alveolar macrophages, rather than lung epithelial cells. In 
addition to the airway epithelium, the target for CF gene therapy, cells in the peripheral lung 
(a mixture of pneumocytes and macrophages) are transduced after bolus administration of the 
viral vector by nasal sniffing which may lead to pooling of liquid in the peripheral lung. To 
determine transduction efficiency of airway epithelium more accurately the viral vector needs 
to be administered by nebulisation. Further work is now warranted to determine whether 
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F/HN-SIV is stable in clinically approved nebulisers and that virus production can be scaled 
up to the extent required for clinical studies. We are currently (a) assessing if F/HN-SIV is 
stable in clinically approved nebulisers and preliminary results indicate that infectivity after 
nebulisation is retained (data not shown) and (b) scaling up vector production to allow us to 
move into in vivo nebulisation experiments in the near future. 
 
Whilst expression levels in the lung are completely stable over the 2 year study period, those 
in the nasal epithelium declined by approximately 60%.  The latter is consistent with our 
previous data 
11
 and may relate to different cell types being transduced in the lung (airway 
epithelium and alveolar cells) and nose (mainly ciliated airway epithelial cells) 
11
 as well as 
different turn-over rates of these cells at these two sites.  Although, we do not have 
information about turn-over of nasal airway epithelium, Rawlins et al have shown that the 
half-life of ciliated airway epithelial cells in the mouse trachea and lung differs (trachea: 
average half-life 6 months, lung: average half-life of 17 months) 
13
.  
We have previously shown that prolongation of contact time between non-viral gene transfer 
agents and the airway epithelium significantly increases gene expression 
20
. In our previous 
study, we therefore slowly perfused F/HN-SIV (1.3 l/min) onto the mouse nasal epithelium 
to maximise transduction 
11
. Transduction efficiency in the nasal epithelium after 
administration of a bolus of fluid which is rapidly (seconds) sniffed into the lung led to 
similar levels of photon emission. This implies that brief contact time between F/HN-SIV and 
the target cell may be sufficient for efficient vector uptake into the cells, which is an 
important factor for clinical translation.  F/HN-SIV, therefore, mimics Sendai virus 
2
 from 
which the F and HN envelope proteins were derived.  
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We and others have previously shown that repeated administration of lentiviral vectors to the 
mouse nasal epithelium is feasible 
10;11
. To move our translational research a step closer to 
clinical relevance we now assessed repeat administration of the vector in the lung. Two types 
of repeat administration experiments were performed; (1) daily and (2) monthly. The former 
was assessed because it is conceivable that the total volume required for delivery of a specific 
vector titre to the human lung may be too large for a single dose and administration may have 
to be split into several doses to accommodate the volume. Here, we show that daily repeat 
administration is feasible and leads to a dose-related increase in gene expression. Although 
important, we have not yet addressed the question if “split-dose” delivery of a specific vector 
titre (e.g 10 doses of 10
7
 TU) offers advantages over “single-dose” delivery of the same 
vector titre (e.g 1 dose of 10
8
 TU) which may also be a relevant translational research 
question. Although efficient daily-repeat administration is encouraging, this time-frame is 
generally not considered to be sufficient to induce robust immune responses to the viral 
vector. To confirm that long-term F/HN-SIV repeat administration to the lower airways is 
feasible viral vector was administered monthly over a 3-month period. This dosing interval 
may be of clinical relevance and is also an accepted timeframe for the induction of robust 
immune responses. Uniquely for a viral vector (in our hands) luciferase expression levels 
after one and three doses were identical and more than 4 log orders higher than in 
untransduced control mice.  
Another important consideration for translational development of a gene transfer agent is 
safety. The occurrence of leukaemia and myelodysplasia in some patients with primary 
immunodeficiencies after treatment with gamma retroviral vector-transduced bone marrow 
21
 
raises concerns about the safety of integrating viral vectors. The risk of insertional 
mutagenesis in slowly turning over differentiated lung epithelium is unknown, but is likely to 
be lower than in rapidly dividing bone marrow cells. In addition the improved design of self-
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inactivating lentiviral vectors has improved safety 
21
. Here we compared survival, weight and 
lung histology during a 24 month study period and did not see any differences between 
F/HN-SIV and PBS treated mice. We included only female mice in the study as they can be 
more readily housed together for prolonged periods of time. It is unlikely that the toxicology 
profile in male mice would be significantly different. However, before progression into 
clinical trial a GLP-toxicology study, including male and female animals as well as dose-
ranging, will have to be performed. Despite the encouraging toxicology profile of our current 
vector configuration we plan to assess further modifications before final vector selection for 
clinical trials, including the use of mammalian promoters as well as ubiquitous chromatin 
opening elements (UCOE). The former have been shown to reduce the risk of insertional 
mutagenesis compared to strong viral promoters 
22
; whilst the latter may reduce gene 
silencing 
22
. The ability to administer this vector repeatedly and efficiently also opens the 
possibility of using non-integrating lentiviral vectors 
23
 which may further reduce the 
genotoxic risk.  
As part of our translational pathway we next determined whether F/HN-SIV is able to 
transduce human tissues. We have previously shown that F/HN-SIV can transduce fully 
differentiated human air liquid interface (ALI) cultures when analysed 5 days after 
transduction 
11
. These cultures mimic human airway epithelium and are difficult to transfect 
24
. Here, we have extended these studies, and show that F/HN-SIV-mediated expression in 
ALIs is stable, persists for at least 3 months (the length of the experiment) and is higher than 
GL67A-mediated expression, which in our hands is currently the most efficient non-viral 
vector. Preliminary experiments indicated that in contrast to lipid-mediated gene transfer, 
F/HN-SIV does not appear to damage the ALI cultures, but more extensive studies are 
required to determine acute toxicity in vitro and in vivo.  
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To further evaluate the viral vector in even more relevant tissues we assessed freshly obtained 
human primary airway cells and showed that F/HN-SIV-Lux transduction leads to significant 
levels of luciferase expression. We performed only short-term (24 hr) experiments to avoid 
potential cell division which would have affected interpretation of the results. Collection of 
primary cells by nasal brushings exposes the basolateral membrane of these cells and we 
cannot exclude the possibility that the vector may have entered the cells via this route. 
However, experiments performed in mice in vivo and in ALI cultures clearly show that 
F/HN-SIV can transduce airway epithelial cells when applied to the apical membrane without 
the need to co-administer agents to open tight junctions. There was no difference in gene 
expression when cells were transduced with an MOI of 25 or 250. In future experiments the 
MOI will be further reduced to determine the minimum MOI for efficient transduction.   
We also assessed F/HN-SIV in precision cut human lung slices. Expression in both 
experiments was stable and persisted for at least 14 days, after which the experiment was 
terminated because of reduced tissue viability. Although we have not determined which cells 
express the recombinant protein these studies show that persistent SIV-mediated transduction 
into human pulmonary cells is feasible and is not prevented by viral restriction factors. We 
also transduced ovine lung slices, which are generally more resilient when cultured (Nikki 
Newman personal communication); stable luciferase expression was detectable for at least 26 
days. These data support the future use of these models in the clinical development of this 
vector.  
Sendai-virus shares high sequence homology with human parainfluenza virus (HPIV) and 
pre-existing immunity may be a factor.  Interestingly, Slobod KS et al assessed Sendai virus-
vaccination against HPIV and reported evidence of immunogenicity in three of nine 
vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous 
exposure to human PIV-1 
25
. Although this initial study is encouraging the effects of pre-
21 | P a g e  
 
existing humoral immunity on virus transduction efficiency is something we will address as a 
high priority.  
Gene transfer to the airway epithelium is more difficult than originally anticipated. Until now 
viral gene transfer agents have not been useful for the treatment of chronic lung disease such 
cystic fibrosis (CF), due to immunogenicity which prevent successful repeat administration.  
Lentivirus-based vectors are a notable exception. Moving novel therapies to the clinic 
requires that relevant evidence for both safety and efficacy is gathered in appropriate models. 
Here, we begin to place this vector onto a translational pathway to the clinic and provide a 
body of supportive evidence for F/HN-pseudotyped SIV as a potential gene transfer agent for 
CF including a) life-time gene expression and efficient repeat administration in mouse lung, 
b) lack of chronic toxicity, c) persistent gene expression in human ex vivo models. 
The data presented here support F/HN-SIV as a promising vector for pulmonary gene 
therapy, with potential for many diseases including CF. We are currently undertaking the 
next critical steps (vector optimisation and virus production) in this developmental process 
towards clinical evaluation and are improving vector optimisation and viral production 
methods to support progression into early phase trials.  
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Figure Legends 
Figure 1: F/HN-SIV transduction leads to persistent gene expression in mouse lung 
Mice were transduced with F/HN-SIV-Lux (5x10
8
 TU/mouse) by nasal sniffing (n=8 in two 
independent experiments) or received PBS (negative controls, n=6). Luciferase expression 
was quantified using bioluminescence imaging or in tissue homogenate at regular intervals 
for up to 24 months. (A) Bioluminescence in vivo imaging 2 to 22 months after transduction. 
Representative images of two mice reaching the 22 months time point are shown. (B) 
Quantification of in vivo bioluminescence over time (black lines, n=8) or PBS (red lines, 
n=6). Each line represents photon emission over time in one animal. Solid and dotted lines 
represent independent experiments. ***=p<0.005 when compared to month 2. 
Bioluminescent in vivo imaging (BLI) (C) and luciferase expression in lung tissue 
homogenate (D) was repeated at regular intervals over  24 month in a third  independent 
experiment (10
7
 TU/mouse, n=8-12/time-point). For technical reasons BLI could only be 
performed between 6 and 24 months after gene transfer. ***=p<0.005 when compared to 
month 6.  Quantification of luciferase expression in lung tissue homogenate was performed at 
regular intervals over the 24 months study period. Each dot represents one animal. Horizontal 
bars represent the group median. (E) Correlation between luciferase expression quantified in 
tissue homogenates and photons emitted from extracted lungs (representative images from 11 
extracted lungs are shown). Each dot represents one animal. (F) Detection of green 
fluorescent protein (GFP) expression in lung after transduction with F/HN-SIV-GFP (10
8
 
TU/mouse). Transduced GFP positive cells were identified using fluorescent microscopy 
(original magnification x20). (i) PBS treated negative control. (ii and iii) Tissue sections from 
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F/HN-SIV-GFP treated mice showing GFP positive cells in airways (arrows) and alveoli. 
Representative images from four mice/group are shown.  
 
Figure 2: F/HN-SIV requires only short contact time to achieve efficient transduction 
Luciferase expression was compared in mice receiving F/HN-SIV-Lux (3-4x10
8
 TU/mouse in 
100l) by slow perfusion (1.3 l/min, n=10) or as bolus administration by nasal sniffing 
(n=8). (A) Bioluminescence in vivo signal in the mouse nose. Representative images of three 
mice are shown. (B) Quantification of in vivo bioluminescence in mouse nose after slow 
perfusion or nasal sniffing of the vector. Each dot represents one animal. Horizontal bars 
represent the group median. (C) Bioluminescence in vivo signal in mouse nose after 
intraperitoneal (IP) or intranasal (IN) administration of luciferin. Representative images of 
two of five mice are shown. Luciferase expression after slow perfusion of the F/HN-SIV-Lux 
has been published previously 
11
.  
 
Figure 3: Daily and monthly repeat administration to the lung is feasible 
(A) Daily re-administration: Mice (n=8/group) were treated with either F/HN-SIV-Lux for 10 
days (10
6
 TU/day) or with D-PBS for 5 days followed by 5 days of F/HN-SIV-Lux (10
6
 
TU/day)  or with D-PBS for 9 days followed by 1 day of F/HN-SIV-Lux  (10
6
 TU). 
Luciferase expression was analyzed 28 days after F/HN-SIV-Lux administration. (B) 
Monthly re-administration: Mice were either treated with one dose of F/HN-SIV-Lux (single 
dose group) or two doses of F/HN-SIV-GFP (day 0, day 28), followed by F/HN-SIV-Lux on 
day 56 (repeat dose group). All mice receive 10
7
 TU/dose (n=20/group) and gene expression 
was analyzed 28 days after F/HN-SIV-Lux administration. Each dot represents one animal. 
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Horizontal bars represent the group median. Dotted line represents negative control values, 
*** p<0.0001 when compared to 5 and 10 doses, **p<0.01 when compared to 10 doses. 
 
 Figure 4: No evidence of chronic toxicity during 2 year follow-up period 
(A) 24 months survival of mice treated with F/HN-SIV-Lux (10
7 
TU/mouse, n=99 at start of 
the experiment) or PBS (n=48 at start of the experiment) by nasal sniffing. (B-D) Comparison 
of lymphocytes (B), oedema (C) and inflammation (D) in mouse lung 24 months after F/HN-
SIV-Lux or PBS treatment.  Each dot represents one animal. Horizontal bars represent the 
group median. 
 
Figure 5: Persistent gene expression in differentiated ALI cultures  
Differentiated human air liquid interface cultures were transduced with F/HN-SIV-Lux at 
MOI 25 or 250 (n=5/group), transfected with GL67A complexed to a eukaryotic expression 
plasmid expressing luciferase (10 g pCIKLux per ALI equivalent to 3x1012 plasmids and an 
approximate MOI of 7x10
6
) (n=3) or treated with PBS (negative control, n=3). Luciferase 
expression was followed using BLI for 3 months. (A) Representative images are shown. (B) 
Quantification of luciferase expression over 3 months.  
 
Figure 6: F/HN-SIV transduces primary human pulmonary cells  
(A) Microscopic section showing primary human airway epithelial cells obtained from nasal 
brushings (left, GC=goblet cell, CC=ciliated airway epithelial cell) or human lung slices 
(right, AW=airway, P=parenchyma). (B) Nasal brushings were transduced with F/HN-SIV-
Lux at an MOI of 25 and 250 or treated with PBS (negative control) and luciferase expression 
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was quantified 24 hr after transduction. Each dot represents one sample. Horizontal bars 
represent the group median. ***=p<0.005 when compared to negative controls. (C) Human 
lung slices were transfected with F/HN-SIV-Lux (2x10
7
 TU/slice) or remained untransfected 
(negative control) and luciferase expression quantified 2, 7 and 14 days after transduction. 
Two independent experiments were performed (open and closed symbols). (D) Sheep lung 
slices were transfected with F/HN-SIV-Lux (2x10
7
 TU/slice) or remained untransfected 
(negative control) and luciferase expression quantified up to 26 days after transduction. Two 
independent experiments were performed (open and closed symbols). Each dot represents one 
animal. Horizontal bars represent the group median. *=p<0.05, **=p<0.01, ***=p<0.005 
when compared to negative control. 
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Camera: IVIS 82, DW34
Experiment: SIV 10E9
Label: Mouse3,4,5
Comment: W4
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1.0
0.8
0.6
0.4
0.2
x
1
0
6 
Image
Min = -2928.9
Max = 1.0576e+06
p/sec/cm^2/sr
Color Bar
Min = 8000
Max = 1e+06
bkg sub
flat-fielded
cosmic
Click # SW20070525113149
25 May 2007 11:32:03
Bin:M (4), FOV12, f1, 10m
Filter: Open
Camera: IVIS 82, DW34
Series: 4-6
IACUC #: 
Experiment: SiV-lux duration-1
Label: SiV-lux(4-6)
Comment: 10x4
Analysis Comment: 
1.0
0.8
0.6
0.4
0.2
x
1
0
6 
Image
Min = -3465.6
Max = 1.4753e+06
p/sec/cm^2/sr
Color Bar
Min = 8000
Max = 1e+06
bkg sub
flat-fielded
cosmic
Perfusion Nasal Sniffing 
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Filter: Open
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Filter: Open
Camera: IVIS 82, DW34
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Figure 3A 
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Click # SW20090722152437
Wed, Jul 22, 2009 15:24:45
Bin:M (4), FOV12, f1, 1m
Filter: Open
Camera: IVIS 82, DW34
Experiment: untransfected
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Figure 5B 
Human nasal brushings 
60% columnar epithelium 20% goblet cells 
Figure 6A 
AW 
P 
GC 
CC 
Figure 6B 
MOI 25 MOI 250  
104 
105 
106 
L
u
ci
fe
ra
se
 E
x
p
re
ss
io
n
 
 (
R
L
U
/m
g
 p
ro
te
in
) 
*** *** 
Negative  
Control 
Negative 
control 
day 2 day 7 day 14 
104 
105 
106 
107 
108 
109 
*** *** * 
L
u
ci
fe
r
a
se
 E
x
p
re
ss
io
n
 
 (
R
L
U
/m
g
 p
ro
te
in
) 
Figure 6C 
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Figure 6D 
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B Lymphocytes C Oedema 
D Inflammation 
Months 
after treatment 
PBS treated mice 
Weight (g) 
SIV treated mice 
Weight (g) 
6 24.9 (0.5) 
n=48 
25.4 (0.3) 
n=71 
15 30.7 (0.7) 
n=47 
 
31.4 (0.8) 
n=35 
24 30.1 (1.4) 
n=36 
29.1 (1.1) 
n=12 
 
Table 1: Mouse weights 6, 15 and 24 months after lung transduction with F/HN-SIV-Lux or 
PBS administration. Mean weight (±SEM) are shown. There were no differences between 
PBS and SIV treated mice. 
Treatment  Death  
(Months after 
treatment 
Diagnosis 
PBS 15 Found dead 
PBS 18 Lymphoma 
PBS 19 Lymphoma 
PBS 20 Lymphoma 
PBS 20 Inconclusive  
PBS 21 No pathology found 
PBS 21 Lymphoma 
PBS 23 No pathology found 
PBS 23 Found dead 
PBS 23 Lymphoma 
PBS 24 Found dead 
   
SIV 3 Peritonitis 
SIV 13 Found dead 
SIV 17 Found dead 
SIV 19 Pancreatic tumour 
SIV 21 Multi-organ inflammation 
SIV 24 Found dead 
SIV 24 Multifocal lymphocytic inflammation 
 
Table 2: Cause of mortality of PBS and F/HN-SIV treated mice over a 24 months period 
